IDNA
·NYSE
--
--(--)
--
--(--)
Key Stats
Assets Under Management
133.96MUSD
Fund Flows (1Y)
-10.80MUSD
Dividend Yield
1.15%
Discount/Premium to NAV
-0.06%
Shares Outstanding
5.00M
Expense Ratio
0.47%
About iShares Genomics Immunology and Healthcare ETF
Issuer
BlackRock Fund Advisors
Brand
iShares
Inception Date
Jun 11, 2019
Structure
Open-Ended Fund
Index Tracked
NYSE FactSet Global Genomics and Immuno Biopharma Index
Management Style
Passive
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
BlackRock Fund Advisors
Distributor
BlackRock Investments LLC
IDNA holds a concentrated portfolio of global companies in the biopharmaceutical and healthcare equipment and services industries that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. In addition to these industry screens, companies must also meet certain size and liquidity measures for index eligibility. The underlying index then assigns a "Relationship Keyword Score" to each of the eligible companies using the FactSet Supply Chain Relationships database in search for keywords related to 'Genomics and Immuno Biopharmaceutical' products and technologies. The top 50 names with the highest scores are included in the index. Holdings are weighted by market-cap and are constrained such that no individual security exceeds 4% weight of the portfolio. The index rebalances semi-annually.
Classification
Asset Class
Equity
Category
Sector
Focus
Theme
Niche
Genomic Advancements
Strategy
Vanilla
Geography
U.S.
Weighting Scheme
Market Cap
Selection Criteria
Market cap
Returns
1-Month | 3-Month | YTD | 1-Year | 3-Year | 5-Year | |
|---|---|---|---|---|---|---|
Price Performance | -1.88% | +17.49% | +17.70% | +18.22% | +5.67% | -46.33% |
NAV Total Return | -2.13% | +16.78% | +19.13% | +18.81% | +13.89% | -42.07% |
Ratings
No data is currently available
Ainvest’s AI-powered ETF Scoring Algorithm, built to help retail investors make smarter, data-driven decisions. Leveraging deep learning, reinforcement learning, and large language models, the algorithm scores ETFs across five key dimensions: Fund Flow, Momentum, Safety, Fundamentals, and Performance. Each factor is weighted by its correlation to future returns, resulting in a single, actionable score. Backtested over five years with consistently strong predictive accuracy. Ainvest brings institutional-grade artificial intelligence to everyday investors—transforming complexity into clarity with every score.
Holdings Analysis
Sector
Healthcare
100.00%
Healthcare
100.00%
Asset
Region
71.99%
22.63%
5.39%
Category
Ratio
North America
71.99%
Europe
22.63%
Asia
5.39%
Investment Style
Mega
Large
Medium
Multi
Small
Value
Blend
Growth
Multi-Cap Blend
Provides exposure to companies of various sizes that exhibit both growth and value characteristics. This category offers a diversified portfolio with a mix of market caps.
Top 10 Holdings
Symbol
Ratio
MRNA
Moderna
4.63%
TAKEDA PHARMACEUTICAL LTD
4.30%
BAYER AG
4.27%
REGN
Regeneron
4.27%
ROCHE HOLDING PAR AG
4.23%
MRK
Merck
4.18%
GENMAB
4.14%
EXEL
Exelixis
4.11%
RVMD
Revolution Medicines
3.99%
VRTX
Vertex Pharmaceuticals
3.98%
Top 10 Weight 42.1%
66 Total Holdings
Dividends
Dividend Payout History
Declaration Date | Record Date | Payment Date | Amount |
|---|---|---|---|
| 2025-12-16 | 2025-12-16 | 2025-12-19 | 0.155 |
| 2025-06-16 | 2025-06-16 | 2025-06-20 | 0.153 |
| 2024-12-17 | 2024-12-17 | 2024-12-20 | 0.111 |
| 2024-06-11 | 2024-06-11 | 2024-06-17 | 0.111 |
| 2023-12-20 | 2023-12-21 | 2023-12-27 | 0.169 |
| 2023-06-07 | 2023-06-08 | 2023-06-13 | 0.071 |
| 2022-06-09 | 2022-06-10 | 2022-06-15 | 0.136 |
Show more
Premium/Discount Chart
Premium/Discount to NAV
Price
1M
Assets Under Management
Assets Under Management
1M
Fund Flows
Inflows
Outflows
1M
